Health Outcomes Teams Publish Research on Real-World Chronic Hepatitis C Outcomes

June 20, 2014

Hepatitis C treatments that are simpler, shorter in duration, and have more positive safety profiles and greater tolerability will drive improved adherence and effectiveness among patients, according to recent studies conducted by Analysis Group health care consultants. The research, which was based on analysis of a large commercial insurance claims database and led by Managing Principal Eric Wu, was recently featured in Formulary Journal ("Chronic hep C: More effective, better-tolerated therapies still needed, researchers say," June 2014) and also suggested that patients in need of effective therapy would benefit from treatments with fewer contraindications.

The results of these two studies of chronic hepatitis C patients were originally published in Value in Health (May 2014); the data were also presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2014 annual meeting. In the first study, a research team that included Analysis Group Vice President Patrick Lefebvre and Senior Economist Francois Laliberté demonstrated the significant 12-month medical and drug costs of hepatitis C patients utilizing two direct-acting antiviral (DAA) agents, telaprevir ($90,000) and boceprevir ($77,000). In addition to the costs, these complex treatment regimes require multiple daily doses and additional therapies and are often accompanied by negative side effects, such as anemia and rash. All of this contributed to the significant percentage of patients in this study who did not complete the minimum recommended therapy duration for these two DAA agents (54 percent and 74 percent, respectively).

The second study, which included Analysis Group Vice President Dendy Macaulay, targeted the presence of contraindications in untreated chronic hepatitis C patients to two essential elements -- ribavirin and peginterferon alpha -- of chronic hepatitis C therapy. Reflecting on the study's findings, Dr. Wu explains that the researchers "found that over 60 percent of untreated chronic hepatitis C patients had diagnoses for contraindicated conditions, with arterial hypertension, hepatic decompensation, major system impairment, and psychiatric depression being the most common contraindications." This demonstrates the need for the expansion of available treatments with fewer contraindications.

Read the Formulary Journal article

Read more about our presence at the 2014 ISPOR Conference